-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
(4R,12aS)-7-(benzyloxy)-4-Methyl-3,4-dihydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-6,8(12H,12aH)-dione is a pharmaceutical compound that is used in the treatment of various diseases such as cancer and autoimmune disorders.
As a pharmaceutical compound, it is considered an upstream product, which is defined as a product that is used as a raw material in the manufacture of a finished drug.
The synthesis of (4R,12aS)-7-(benzyloxy)-4-Methyl-3,4-dihydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-6,8(12H,12aH)-dione involves a number of steps that require specialized equipment and infrastructure.
The synthesis process involves a number of chemical reactions such as alkylation, acylation, and hydrolysis, which require the use of specialized reagents and solvents.
Once the synthesis process is complete, the (4R,12aS)-7-(benzyloxy)-4-Methyl-3,4-dihydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-6,8(12H,12aH)-dione is then purified and isolated using various chromatographic techniques.
The resulting pure compound is then used as an upstream product in the manufacture of a finished drug.
The finished drug is considered a downstream product, which is defined as a product that is produced using one or more upstream products.
The manufacture of a finished drug involves a number of steps that include formulation, filling, and packaging.
These steps require the use of various equipment and infrastructure, such as mixing and granulation equipment, filling machines, and packaging machines.
The use of (4R,12aS)-7-(benzyloxy)-4-Methyl-3,4-dihydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-6,8(12H,12aH)-dione in the manufacture of a finished drug is a critical step in the treatment of various diseases.
The purity and efficacy of the finished drug depend on the quality of the upstream products used in its manufacture, including (4R,12aS)-7-(benzyloxy)-4-Methyl-3,4-dihydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-6,8(12H,12aH)-dione.
In conclusion, (4R,12aS)-7-(benzyloxy)-4-Methyl-3,4-dihydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-6,8(12H,12aH)-dione is an important upstream product in the pharmaceutical industry, and its use in the manufacture of a finished drug is critical to the treatment of various diseases.
The industry that is involved in the production and supply of pharmaceutical compounds such as (4R,12aS)-7-(benzyloxy)-4-Methyl-3,4-dihydro-2H-[1,3]oxazino[3,2-d]pyrido[1,2-a]pyrazine-6,
